347 related articles for article (PubMed ID: 16625842)
1. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats.
Silva AP; Schoeffter P; Weckbecker G; Bruns C; Schmid HA
Eur J Endocrinol; 2005 Sep; 153(3):R7-R10. PubMed ID: 16131595
[TBL] [Abstract][Full Text] [Related]
4. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and its receptor family.
Patel YC
Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
8. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
Weckbecker G; Briner U; Lewis I; Bruns C
Endocrinology; 2002 Oct; 143(10):4123-30. PubMed ID: 12239124
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice.
Kaczmarek P; Singh V; Cashen DE; Yang L; Berk S; Pasternak A; Xiong Y; Shen DM; Hutchins SM; Chapman K; Wiedenmann B; Schaeffer JM; Strowski MZ
Neurogastroenterol Motil; 2010 Feb; 22(2):204-9, e66. PubMed ID: 19754922
[TBL] [Abstract][Full Text] [Related]
10. The release of growth hormone (GH): relation to the thyrotropic- and corticotropic axis in the chicken.
Kühn ER; Geelissen SM; Van der Geyten S; Darras VM
Domest Anim Endocrinol; 2005 Jul; 29(1):43-51. PubMed ID: 15927766
[TBL] [Abstract][Full Text] [Related]
11. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
12. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
13. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies.
Osapay G; Prokai L; Kim HS; Medzihradszky KF; Coy DH; Liapakis G; Reisine T; Melacini G; Zhu Q; Wang SH; Mattern RH; Goodman M
J Med Chem; 1997 Jul; 40(14):2241-51. PubMed ID: 9216843
[TBL] [Abstract][Full Text] [Related]
14. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
15. Novel molecular aspects of pituitary adenomas.
Hubina E; Ruscica M; Nanzer AM; Czirják S; Góth MI; Grossman AB; Korbonits M
J Endocrinol Invest; 2005; 28(11 Suppl International):87-92. PubMed ID: 16625855
[TBL] [Abstract][Full Text] [Related]
16. Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.
Castillo V; Theodoropoulou M; Stalla J; Gallelli MF; Cabrera-Blatter MF; Haedo MR; Labeur M; Schmid HA; Stalla GK; Arzt E
Neuroendocrinology; 2011; 94(2):124-36. PubMed ID: 21525729
[TBL] [Abstract][Full Text] [Related]
17. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
[TBL] [Abstract][Full Text] [Related]
18. Regulation of ghrelin secretion by somatostatin analogs in rats.
Silva AP; Bethmann K; Raulf F; Schmid HA
Eur J Endocrinol; 2005 Jun; 152(6):887-94. PubMed ID: 15941929
[TBL] [Abstract][Full Text] [Related]
19. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
20. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
